18F-FDG uptake changes in liver and mediastinum during chemotherapy in patients with diffuse large B-cell lymphoma

Clinical Nuclear Medicine

Volumn 37, Issue 10, 2012, Pages 949-952

  Ceriani, Luca ^a   Suriano, Sergio ^a   Ruberto, Teresa ^a   Zucca, Emanuele ^a   Giovanella, Luca ^a  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

18F FDG; chemotherapy; interim PET; lymphoma; PET

Indexed keywords

CREATININE; FLUORODEOXYGLUCOSE F 18; GLUCOSE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CREATININE BLOOD LEVEL; DRUG LIVER LEVEL; DRUG TISSUE LEVEL; DRUG UPTAKE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LARGE CELL LYMPHOMA; LIVER; MALE; MEDIASTINUM; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIVER; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MEDIASTINUM; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84866328756     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e318263831d     Document Type: Article

References (30)

1. Kirby AM, Mikhaeel NG. The role of FDG PET in the management of lymphoma: What is the evidence base? Nucl Med Commun. 2007;28:335-354.
2. Kostakoglu L, Coleman M, Leonard JP, et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med. 2002;43:1018-1027.
3. Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography (PET) with fluorine 18 fluorodeoxyglucose ([18F]FDG) predicts outcome in patients with aggressive nonYHodgkin's lymphoma. Ann Oncol. 2002;13:1356-1363.
4. Jerusalem G, Beguin Y, Fassotte MF, et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in nonYHodgkin's lymphoma. Haematologica. 2000;85:613-618.
5. Schot B, van Imhoff G, Pruim J, et al. Predictive value of early 18F-fluorodeoxyglucose positron emission tomography in chemosensitive relapsed lymphoma. Br J Haematol. 2003;123:282-287.
6. Zhao J, Qiao W, Wang C, et al. Therapeutic evaluation and prognostic value of interim hybrid PET/CTwith (18)F-FDG after three to four cycles of chemotherapy in nonYHodgkin's lymphoma. Hematology. 2007;12:423-430.
7. Mikhaeel N, Hutchings M, Fields P, et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high grade nonYHodgkin lymphoma. Ann Oncol. 2005;16:1514-1523.
8. Haioun C, Itti E, Rahmouni A, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: An early prognostic tool for predicting patient outcome. Blood. 2005;206:1376-1381.
9. Zijlstra J, Lindauer-van derWerf G, Hoekstra O, et al. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: A systematic review. Haematologica. 2006;91:522-529.
10. Terasawa T, LAU J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: A systematic review. J Clin Oncol. 2009;27:1906-1914.
11. Meignan M, Gallamini A, Haioun C. Report on the first internationalworkshop on interim-PET scan in lymphoma. Leuk Lymphoma. 2009;50:1257-1260.
12. Mikhaeell NG. Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma: Where arewe now? Leuk Lymphoma. 2009;50:1931-1936.
13. Hutchings M, Mikhaeel NG, Fields PA, et al. Prognostic value of interim FDGPET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005;16:1160-1168.
14. Mikhaeel NG, Timothy AR, O'Doherty MJ, et al. 18-FDGPET as a prognostic indicator in the treatment of aggressive nonYHodgkin's lymphoma: Comparison with CT. Leuk Lymphoma. 2000;39:543-553.
15. Kasamon YL, Wahl RL, Ziessman HA, et al. Phase II study of risk-adapted therapy of newly diagnosed, aggressive nonYHodgkin lymphoma based on midtreatment FDG-PET scanning. Biol Blood Marrow Transplant. 2009; 15:242-248.
16. Mikhaeel NG. Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas. Eur J Nucl Med Mol Imaging. 2006; 33(suppl 1):22-26.
17. Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica. 2006;91: 475-481.
18. Querellou S, Valette F, Bodet-Milin C, et al. FDG-PET/CT predicts outcome in patients with aggressive nonYHodgkin's lymphoma and Hodgkin's disease. Ann Hematol. 2006;85:759-767.
19. Kostakoglu L, Goldsmith SJ, Leonard JP, et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer. 2006;107:2678-2687.
20. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52-59.
21. Horning SJ, Juweid ME, Schoder H, et al. Interim positron emission tomography scans in diffuse large B-cell lymphoma: An independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood. 2010;115:775-777.
22. Juweid ME, Stroobants S, Hoekstra OS, et al. Imaging Subcommittee of International Harmonization Project in Lymphoma. Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571-578.
23. Paquet N, Albert A, Foidart J, et al.Within-patient variability of 18F-FDG: Standardized uptake values in normal tissues. J Nucl Med. 2004;45:784-788.
24. Kanstrup IL, Klausen TL, Boisen-Møller J, et al. Variability and reproducibility of hepatic FDG uptake measured as SUVas well as tissue-to-blood background ratio using positron emission tomography in healthy humans. Clin Physiol Funct Imaging. 2009;29:108-113.
25. Robinson PJ. The effects of cancer chemotherapy on liver imaging. Eur Radiol. 2009;19:1752-1762.
26. Itti E, Juweid ME, Haioun C, et al. Improvement of early 18F-FDG PET interpretation in diffuse large B-cell lymphoma: Importance of the reference background. J Nucl Med. 2010;51:1857-1862.
27. Barrington SF, Quian W, Somer EJ, et al. Concordance between four European Centres reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010;37:1824-1833.
28. Lin C, Itti E, Haioun C, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: suv-based assessment versus visual analysis. J Nucl Med. 2007;48:1626-1632.
29. van Loon J, Offermann C, Ollers M, et al. Early CTand FDG-metabolic tumour volume changes show a significant correlation with survival in stage I-III small cell lung cancer: A hypothesis generating study. Radiother Oncol. 2011;99: 172-175.
30. Brepoels L, De Saint-Hubert M, Stroobants S, et al. Dose-response relationship in cyclophosphamide-treated B-cell lymphoma xenografts monitored with [18F]FDG PET. Eur J Nucl Med Mol Imaging. 2010;37:1688-1695.